LEGN - Legend Biotech Corp - Stock & Dividends

Legend Biotech Corporation is a clinical-stage biopharmaceutical company that focuses on developing innovative cell therapies to treat various types of cancer and other diseases. Through its subsidiaries, the company is involved in the discovery, development, manufacturing, and commercialization of these novel therapies in the United States, China, and globally.

One of the company's lead product candidates is LCAR-B38M, a chimeric antigen receptor (CAR) designed to treat multiple myeloma, a type of blood cancer. In addition to this, Legend Biotech has a robust pipeline of autologous CAR-T product candidates targeting various types of cancer, including Non-Hodgkin's Lymphoma, acute lymphoblastic leukemia, and several types of solid tumors such as gastric, esophageal, pancreatic, colorectal, and lung cancers.

Legend Biotech has established a strategic collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ciltacabtagene autoleucel, a CAR-T cell therapy. This partnership aims to accelerate the development and availability of this innovative treatment to patients in need.

Founded in 2014, Legend Biotech Corporation is headquartered in Somerset, New Jersey, and operates as a subsidiary of Genscript Biotech Corporation. The company is committed to advancing its pipeline of novel cell therapies to improve patient outcomes and transform the treatment landscape for various diseases.